Aurobindo’s CuraTeQ Secures Brazil GMP Nod, Paving Way for Biosimilars Expansion

In what could be a game‑changer for its biosimilars business, Aurobindo Pharma’s subsidiary CuraTeQ Biologics Private Limited has clinched GMP approval from Brazil’s health watchdog, ANVISA. The nod came after a thorough inspection of the Hyderabad‑based facility that ran from May 11‑15, 2026.

During those five days, ANVISA auditors peered into every corner of the plant – from the biological API manufacturing zones to the sterile‑fill lines for pre‑filled syringes and vials. They also examined the packaging, labeling suites, and the quality‑control labs that release the final products. The agency’s report says the facility met all the stringent requirements for producing four biosimilar medicines destined for the Brazilian market.

What’s noteworthy is that this isn’t the first time CuraTeQ’s Hyderabad complex has impressed regulators. It already holds certifications from the European Medicines Agency (EMA) and the World Health Organization (WHO), credentials that now sit comfortably alongside the fresh Brazilian approval.

For Aurobindo Pharma, the development is more than a tick‑box exercise. The company has been eyeing Latin America as a growth frontier, and a GMP seal from ANVISA essentially opens the door to a market of over 210 million people. Analysts see this as a strategic lever to diversify revenue streams beyond India and the United States.

While the approval specifically covers biosimilars, the broader implication is a vote of confidence in CuraTeQ’s manufacturing standards. It reassures investors that the subsidiary can navigate multiple regulatory regimes, a prerequisite for any pharma player hoping to compete on a global stage.

Going forward, Aurobindo expects to roll out the Brazil‑approved biosimilars gradually, aligning supply with demand in the region. The company’s leadership has hinted that similar approvals in other emerging markets could follow, provided the same disciplined approach to quality and compliance is maintained.